Tumor Biology

, Volume 37, Issue 7, pp 9521–9526 | Cite as

Promoter methylation and expression of CDH1 and susceptibility and prognosis of eyelid squamous cell carcinoma

Original Article
  • 97 Downloads

Abstract

Eyelid skin tumors are the most frequent type of cancer in ophthalmology. And, eyelid squamous cell carcinoma (SCC) accounts for a large part of it. CDH1 encodes E-cadherin, a glycoprotein that plays an important part in cell–cell interaction. Loss of CDH1 function was suspected to be associated with tumorigenesis. Methylation of CDH1 promotors can alter the expression of its protein and is also considered as a contributor to various cancers. In this study, CDH1 methylation and expression profile as well as prognosis of 38 cases of eyelid SCC and the corresponding adjacent tissues were analyzed to clarify the role of CDH1 methylation in SCC carcinogenesis and prognosis. Methylation was detected by PCR, and CDH1 expression was evaluated by immunohistochemistry. We observed that CDH1 methylation is significantly correlated with decreased CDH1 protein expression in eyelid SCC patients. Patients with methylation and low expression of CDH1 are significantly associated with advanced and aggressive phenotypes. Therefore, CDH1 methylation and CDH1 expression are both independent prognostic factors for prognosis of eyelid SCC patients.

Keywords

Eyelid squamous cell carcinoma E-cadherin Methylation CDH1 Prognosis 

Notes

Compliance with ethical standards

Conflicts of interest

None

References

  1. 1.
    Deprez M, Uffer S. Clinicopathological features of eyelid skin tumors. A retrospective study of 5504 cases and review of literature. Am J Dermatopathol. 2009;31:256–62.PubMedGoogle Scholar
  2. 2.
    Lee SB, Saw SM, Au Eong KG, Chan TK, Lee HP. Incidence of eyelid cancers in Singapore from 1968 to 1995. Br J Ophthalmol. 1999;83:595–7.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Lin HY, Cheng CY, Hsu WM, Kao WH, Chou P. Incidence of eyelid cancers in taiwan: a 21-year review. Ophthalmology. 2006;113:2101–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Cook Jr BE, Bartley GB. Epidemiologic characteristics and clinical course of patients with malignant eyelid tumors in an incidence cohort in Olmsted County, Minnesota. Ophthalmology. 1999;106:746–50.CrossRefPubMedGoogle Scholar
  5. 5.
    Hollestein LM, de Vries E, Nijsten T. Trends of cutaneous squamous cell carcinoma in the Netherlands: increased incidence rates, but stable relative survival and mortality 1989–2008. Eur J Cancer. 2012;48:2046–53.CrossRefPubMedGoogle Scholar
  6. 6.
    Yin VT, Merritt HA, Sniegowski M, Esmaeli B. Eyelid and ocular surface carcinoma: diagnosis and management. Clin Dermatol. 2015;33:159–69.CrossRefPubMedGoogle Scholar
  7. 7.
    Neale RE, Weissenborn S, Abeni D, Bavinck JNB, Euvrard S, Feltkamp MCW, et al. Human papillomavirus load in eyebrow hair follicles and risk of cutaneous squamous cell carcinoma. Cancer Epidemiol Biomark Prev. 2013;22:719–27.CrossRefGoogle Scholar
  8. 8.
    Sullivan TJ, Boulton JE, Whitehead KJ. Intraepidermal carcinoma of the eyelid. Clin Exp Ophthalmol. 2002;30:23–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Faustina M, Diba R, Ahmadi MA, Esmaeli B. Patterns of regional and distant metastasis in patients with eyelid and periocular squamous cell carcinoma. Ophthalmology. 2004;111:1930–2.CrossRefPubMedGoogle Scholar
  10. 10.
    Asiaf A, Ahmad ST, Aziz SA, Malik AA, Rasool Z, Masood A, et al. Loss of expression and aberrant methylation of the cdh1 (e-cadherin) gene in breast cancer patients from Kashmir. Asian Pac J Cancer Prev : APJCP. 2014;15:6397–403.CrossRefPubMedGoogle Scholar
  11. 11.
    Ibarrola-Villava M, Llorca-Cardenosa MJ, Tarazona N, Mongort C, Fleitas T, Perez-Fidalgo JA, et al. Deregulation of arid1a, cdh1, cmet and pik3ca and target-related microrna expression in gastric cancer. Oncotarget. 2015;6:26935–45.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Liang SC, Yang CY, Tseng JY, Wang HL, Tung CY, Liu HW, et al. Abcg2 localizes to the nucleus and modulates cdh1 expression in lung cancer cells. Neoplasia (New York, NY). 2015;17:265–78.CrossRefGoogle Scholar
  13. 13.
    Martinelli M, Palmieri A, Rodia MT, Cura F, Scapoli L, Ugolini G, et al. Cdh1 polymorphisms and low expression of e-cadherin and beta-catenin in colorectal cancer patients. J Biol Regul Homeost Agents. 2015;29:89–96.PubMedGoogle Scholar
  14. 14.
    Pei Y, Wang P, Liu H, He F, Ming L. Foxq1 promotes esophageal cancer proliferation and metastasis by negatively modulating cdh1. Biomed Pharmacother. 2015;74:89–94.CrossRefPubMedGoogle Scholar
  15. 15.
    Zhao L, Wang YX, Xi M, Liu SL, Zhang P, Luo LL, et al. Association between e-cadherin (cdh1) polymorphisms and pancreatic cancer risk in Han Chinese population. Int J Clin Exp Pathol. 2015;8:5753–60.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Fatemi M, Pao MM, Jeong S, Gal-Yam EN, Egger G, Weisenberger DJ, et al. Footprinting of mammalian promoters: use of a cpg DNA methyltransferase revealing nucleosome positions at a single molecule level. Nucleic Acids Res. 2005;33, e176.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Kulis M, Esteller M. DNA methylation and cancer. Adv Genet. 2010;70:27–56.PubMedGoogle Scholar
  18. 18.
    Qu Y, Dang S, Hou P. Gene methylation in gastric cancer. Clin Chim Acta Int J Clin Chem. 2013;424:53–65.CrossRefGoogle Scholar
  19. 19.
    Xue M, Lai SC, Wang LJ. Non-invasive DNA methylation biomarkers in colorectal cancer: a systematic review. J Dig Dis. 2015.Google Scholar
  20. 20.
    Marx A, Chan JK, Coindre JM, Detterbeck F, Girard N, Harris NL, et al. The 2015 world health organization classification of tumors of the thymus: continuity and changes. J Thoracic Oncol : Off Publ Int Assoc Stud Lung Cancer. 2015;10:1383–95.CrossRefGoogle Scholar
  21. 21.
    Jacot W, Thezenas S, Senal R, Viglianti C, Laberenne AC, Lopez-Crapez E, et al. Brca1 promoter hypermethylation, 53bp1 protein expression and parp-1 activity as biomarkers of DNA repair deficit in breast cancer. BMC Cancer. 2013;13:523.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Shargh SA, Sakizli M, Khalaj V, Movafagh A, Yazdi H, Hagigatjou E, et al. Downregulation of e-cadherin expression in breast cancer by promoter hypermethylation and its relation with progression and prognosis of tumor. Med Oncol (Northwood, London, England). 2014;31:250.CrossRefGoogle Scholar
  23. 23.
    Diniz-Freitas M, Garcia-Caballero T, Antunez-Lopez J, Gandara-Rey JM, Garcia-Garcia A. Reduced e-cadherin expression is an indicator of unfavourable prognosis in oral squamous cell carcinoma. Oral Oncol. 2006;42:190–200.CrossRefPubMedGoogle Scholar
  24. 24.
    Zhai X, Zhu H, Wang W, Zhang S, Zhang Y, Mao G. Abnormal expression of emt-related proteins, s100a4, vimentin and e-cadherin, is correlated with clinicopathological features and prognosis in hcc. Med Oncol (Northwood, London, England). 2014;31:970.CrossRefGoogle Scholar
  25. 25.
    Abascal MF, Besso MJ, Rosso M, Mencucci MV, Aparicio E, Szapiro G, et al. Cdh1/e-cadherin and solid tumors. An updated gene-disease association analysis using bioinformatics tools. Comput Biol Chem. 2015;60:9–20.CrossRefPubMedGoogle Scholar
  26. 26.
    Li XW, Shi BY, Yang QL, Wu J, Wu HM, Wang YF, et al. Epigenetic regulation of cdh1 exon 8 alternative splicing in gastric cancer. BMC Cancer. 2015;15:954.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Nelson WJ, Nusse R. Convergence of wnt, beta-catenin, and cadherin pathways. Science (New York, NY). 2004;303:1483–7.CrossRefGoogle Scholar
  28. 28.
    Dou CY, Fan YC, Cao CJ, Yang Y, Wang K. Sera DNA methylation of cdh1, dnmt3b and esr1 promoters as biomarker for the early diagnosis of hepatitis b virus-related hepatocellular carcinoma. Dig Dis Sci. 2015.Google Scholar
  29. 29.
    Lu H, Liu B, Zhang FJ, Zhang J, Dong R, Chen L, et al. The e3 ligase apc/c-cdh1 regulates mef2a-dependent transcription by targeting sumo-specific protease 2 for ubiquitination and degradation. Cell Cycle. 2014;13:3892–902.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Wang D, Su L, Huang D, Zhang H, Shin DM, Chen ZG. Downregulation of e-cadherin enhances proliferation of head and neck cancer through transcriptional regulation of egfr. Mol Cancer. 2011;10:116.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  1. 1.Department of OphthalmologyJinan Military General HospitalJinanChina
  2. 2.Department of Rehabilitation and PhysiotherapyThe First Affiliated Hospital, Chinese PLA General HospitalBeijingChina

Personalised recommendations